0 58

Cited 14 times in

Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis

Authors
 Wonyoung Cho  ;  Sangil Park  ;  Hyeon Jin Kim  ;  Myeongcheol Lee  ;  Yong Sung Choi  ;  Seung Geun Yeo  ;  Jinseok Lee  ;  Ai Koyanagi  ;  Louis Jacob  ;  Lee Smith  ;  Masoud Rahmati  ;  Suhana Ahmad  ;  Guillaume Fond  ;  Laurent Boyer  ;  Sang Youl Rhee  ;  Seung Won Lee  ;  Jae Il Shin  ;  Ho Geol Woo  ;  Dong Keon Yon 
Citation
 REVIEWS IN MEDICAL VIROLOGY, Vol.34(1) : e2508, 2024-01 
Journal Title
REVIEWS IN MEDICAL VIROLOGY
ISSN
 1052-9276 
Issue Date
2024-01
MeSH
Disease Outbreaks ; Exanthema* ; Fever ; HIV Seropositivity* ; HIV-1* ; Humans ; Mpox (monkeypox)* ; Public Health
Keywords
2003-2021 ; 2022 ; clinical feature ; comparison ; mpox ; outbreak ; prevalence ; symptom
Abstract
On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003–2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword “monkeypox” and “mpox” up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52–17.08), fever (0.68, 0.49–0.94), pruritus (0.25, 0.19–0.32), myalgia (0.50, 0.31–0.81), headache (0.56, 0.35–0.88), skin ulcer (0.32, 0.17–0.59), abdominal symptom (0.29, 0.20–0.42), pharyngitis (0.32, 0.18–0.58), nausea or vomiting (0.15, 0.02–0.93), conjunctivitis (0.11, 0.03–0.38), concomitant infection with HIV (1.70, 0.95–3 0.04), and death (0.02, 0.001–0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.
Full Text
https://onlinelibrary.wiley.com/doi/10.1002/rmv.2508
DOI
10.1002/rmv.2508
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Shin, Jae Il(신재일) ORCID logo https://orcid.org/0000-0003-2326-1820
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/201097
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links